Hello, everyone, and nice to see you again. We hope the weekend was relaxing and enjoyable. Now, though, the time has come to resume the routine, although there is suspicion this may be a quiet day due to the holiday here on this side of the pond. Nonetheless, we are as busy as ever with meetings and deadlines. So please join us as we brew our mandatory cup of stimulation and dig in. Hope your own day goes well and do stay in touch...
Novo Nordisk CEO Talks About Prices And Debt-Ridden Governments (Dow Jones)
Pharmasset Expands Hepatitis C Drug Study Again (Associated Press)
FDA Keeps Hold On Insmed Lung Treatment Trial (Reuters)
AstraZeneca Plans $200M Plant In China (Pharma Times)
FTC Orders Teva To Sell Generics Unit In Cephalon Deal (Bloomberg News)
Moshka8 Finds New Life For Old Drugs In Latin America (Bloomberg News)
Pfizer Consolidates Animal Testing Facilities (San Diego Union Tribune)
Indian Prime Minister Holds Meeting Over Pharma M&A (Hindu Business Line)
Pfizer Settles With Teva Over Lipitor In The UK (Pharma Times)
EDITOR’S NOTE: Please check this post for updates throughout the morning
sunrise pic thx to benimoto on flickr
1 Comment
Mokshae8 is the wave of the future for pharmaceutical sales and marketing, and is build on the same economic model the US was built on in 1960-2000, with rising middle class incomes thirsty for the latest and greatest druugs supported a US pharmaceutical industry that was bursting at the seams with growth.
Today's NY Times reports that American middle class incomes have slipped nearly 10%, which means that the American middle class is dying a slow death. The reverse mis true in certain Latin American countries like Brazil, which is a BRIC emerging market. Through Moksha8 and similar ventures, the US pharmaceutical industry will completely reinvent itself within the next 10 years and return to prosperity, only it won't be in the US.